Skip to main content
. 2015 Aug 26;34(5):2319–2324. doi: 10.3892/or.2015.4225

Figure 4.

Figure 4

Trametinib and pazopanib reduce microvessel density. Established CAL62 and 8505C xenograft tumors treated with the indicated drugs for 2–3 weeks were harvested 4 h after dosing. (A) CD31 immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections (DAB as chromogen). (B) Quantification of CD31-reactive foci (see Materials and methods). Both trametinib and pazopanib resulted in significant reduction in CD31-reactive foci (*p<0.05 vs. control; **p<0.005 vs. control).